Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study.

Braden M Johnson, Tony A Pham,Kate J Young,Leonidas E Bantis,Weijing Sun,Anup Kasi

Kansas journal of medicine（2022）

引用 0|浏览1

暂无评分

摘要

There was no statistical difference in survival between the first-, second-, or third-line groups, which may provide justification for its use as a second- or third-line therapy.

查看译文

关键词

EGFR protein,ErbB receptors,cetuximab,colonic neoplasms,human,panitumumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要